Coherus Oncology (CHRS) Convertible Debt (2016 - 2025)

Coherus Oncology has disclosed Convertible Debt across 10 years of filings, most recently posting $228.6 million for Q1 2025.

• In Q1 2025, Convertible Debt rose 0.59% year-over-year to $228.6 million; the TTM figure through Mar 2025 stood at $228.6 million (up 0.59% YoY), while the FY2024 annual figure was $228.2 million, up 0.59% from the prior year.
• Convertible Debt came in at $228.6 million for Q1 2025 at Coherus Oncology, roughly flat from $228.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $332.8 million in Q4 2021 to a low of $223.3 million in Q1 2021.
• Average Convertible Debt over 5 years is $232.3 million, with a median of $226.2 million recorded in 2023.
• Year-over-year, Convertible Debt jumped 183.19% in 2021 and sank 32.21% in 2022.
• Over 5 years, Convertible Debt stood at $332.8 million in 2021, then slumped by 32.21% to $225.6 million in 2022, then climbed by 0.58% to $226.9 million in 2023, then increased by 0.59% to $228.2 million in 2024, then gained by 0.15% to $228.6 million in 2025.
• Per Business Quant data, the three most recent Convertible Debt figures were $228.6 million in Q1 2025, $228.2 million in Q4 2024, and $227.9 million in Q3 2024.